Nektar Therapeutics (NKTR) Operating Income (2010 - 2026)
Nektar Therapeutics (NKTR) posted quarterly Operating Income of -$39.1 million for Q1 2026, up 12.31% year-over-year from -$34.8 million in Q1 2025, and down 41.17% quarter-over-quarter from -$27.7 million in Q4 2025.
Nektar Therapeutics (NKTR) Operating Income (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Operating Income history runs 17 years deep, the most recent figure standing at -$39.1 million for Q1 2026.
- In Q1 2026, Operating Income rose 12.31% year-over-year to -$39.1 million; the TTM figure through Mar 2026 stood at -$134.6 million (down 17.77% YoY), while the FY2025 annual figure was -$140.1 million, down 33.18% from the prior year.
- Operating Income for Q1 2026 stood at -$39.1 million, down from -$27.7 million in the prior quarter.
- The five-year high for Operating Income was $14.3 million in Q4 2024, with the low at -$152.8 million in Q2 2022.
- The 5-year median for Operating Income is -$44.5 million (2025), against an average of -$54.4 million.
- The sharpest annual moves came in 2024 and 2025: Operating Income soared 142.82% in 2024, then sank 292.81% in 2025.
- Nektar Therapeutics' Operating Income stood at -$52.5 million in 2022, then soared by 36.13% to -$33.5 million in 2023, then jumped by 142.82% to $14.3 million in 2024, then tumbled by 292.81% to -$27.7 million in 2025, then tumbled by 41.17% to -$39.1 million in 2026.
- Business Quant data shows NKTR's Operating Income at -$39.1 million in Q1 2026, -$27.7 million in Q4 2025, and -$31.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn | -39.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -39.05 Mn |
| Dec 31, 2025 | -27.67 Mn |
| Sep 30, 2025 | -31.67 Mn |
| Jun 30, 2025 | -36.23 Mn |
| Mar 31, 2025 | -44.54 Mn |
| Dec 31, 2024 | 14.35 Mn |
| Sep 30, 2024 | -34.35 Mn |
| Jun 30, 2024 | -49.77 Mn |
| Mar 31, 2024 | -35.43 Mn |
| Dec 31, 2023 | -33.51 Mn |
| Sep 30, 2023 | -44.86 Mn |
| Jun 30, 2023 | -50.60 Mn |
| Mar 31, 2023 | -134.71 Mn |
| Dec 31, 2022 | -52.47 Mn |
| Sep 30, 2022 | -54.30 Mn |
| Jun 30, 2022 | -152.84 Mn |
| Mar 31, 2022 | -116.56 Mn |
| Dec 31, 2021 | -112.91 Mn |
| Sep 30, 2021 | -113.60 Mn |
| Jun 30, 2021 | -110.21 Mn |